BioSpace News Archive

Iovance Biotherapeutics, Inc. announced that it intends to offer and sell $150 million of shares of its common stock, subject to market and other conditions, in an underwritten public offering.

Clover Biopharmaceuticals, Ltd., a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, provided updates on business and R&D pipeline development.

Acerus Pharmaceuticals Corporation announces that, in connection with its creditor protection proceedings under the Companies’ Creditors Arrangement Act and its previously announced sale and investment solicitation process, the Company completed the previously announced transactions with First Generation Capital Inc. as successful bidder under the SISP.

Zhejiang Doer Biologics Co., Ltd., a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, announced that it has entered into a license agreement with BioNTech SE.

Nicox SA provided details of a U.S. market survey evaluating the commercial potential of NCX 470, a nitric oxide -donating bimatoprost, in development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension and estimated potential global annual net sales for NCX 470.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced that it has submitted a first Clinical Trial Application for OTOF-GT to the UK’s Medicines and Healthcare products Regulatory Agency.

NANOBIOTIX announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3.

Hemogenyx Pharmaceuticals plc announces that the Company has received a full review letter from the U.S. Food and Drug Administration regarding the Investigational New Drug application forthe Company’s product candidate Chimeric Antigen Receptor T-cells for the treatment of acute myeloid leukaemia to the effect that HEMO-CAR-T be put on clinical hold.

Skanska has signed a contract amendment with Oregon Health & Science University for its Hospital Expansion Project in Portland, Oregon, USA.

Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities will present a technical session at BIOPLUS-INTERPHEX KOREA 2023 for biotechs planning regional or global trials.